Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blinded, Randomized, Phase III Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Favipiravir in Participants With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

NCT05279235 is registered in ClinicalTrials.gov with Shanghai Vinnerna Biosciences Co., Ltd. as lead sponsor.

NCT NCT05279235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05279235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blinded, Randomized, Phase III Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Favipiravir in Participants With Moderate to Severe Coronavirus Disease 2019 (COVID-19)
Lead sponsor
Shanghai Vinnerna Biosciences Co., Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
March 14, 2022
Completion date
December 15, 2022
Enrollment
290 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe covid-19